Clinical Efficacy of Combination of Rifampin and Streptomycin for Treatment ofMycobacterium ulceransDisease
- 1 September 2010
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (9) , 3678-3685
- https://doi.org/10.1128/aac.00299-10
Abstract
We have evaluated the clinical efficacy of the combination of oral rifampin at 10 mg/kg of body weight and intramuscular streptomycin at 15 mg/kg for 8 weeks (RS8), as recommended by the WHO, in 160 PCR-confirmed cases ofMycobacterium ulceransdisease. In 152 patients (95%) with all forms of disease from early nodules to large ulcers, with or without edema, the lesions healed without recourse to surgery. Eight patients whose ulcers were healing poorly had skin grafting after completion of antibiotics. There were no recurrences among 158 patients reviewed at the 1-year follow-up. The times to complete healing ranged from 2 to 48 weeks, according to the type and size of the lesion, but the average rate of healing (rate of reduction in ulcer diameter) varied widely. Thirteen subjects had positive cultures forM. ulceransduring or after treatment, but all the lesions healed without further antibiotic treatment. Adverse events were rare. These results confirm the efficacy of RS8 delivered in a community setting.Keywords
This publication has 28 references indexed in Scilit:
- Sensitivity of PCR Targeting Mycobacterium ulcerans by Use of Fine-Needle Aspirates for Diagnosis of Buruli UlcerJournal of Clinical Microbiology, 2009
- Primary Culture of Mycobacterium ulcerans from Human Tissue Specimens after Storage in Semisolid Transport MediumJournal of Clinical Microbiology, 2008
- Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer ( Mycobacterium ulcerans Disease)Antimicrobial Agents and Chemotherapy, 2007
- Mycolactone-Mediated Inhibition of Tumor Necrosis Factor Production by Macrophages Infected withMycobacterium ulceransHas Implications for the Control of InfectionInfection and Immunity, 2007
- Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactoneThe Journal of Experimental Medicine, 2007
- Evidence for an Intramacrophage Growth Phase ofMycobacterium ulceransInfection and Immunity, 2007
- Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-AmikacinAntimicrobial Agents and Chemotherapy, 2007
- Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in MiceAntimicrobial Agents and Chemotherapy, 2001
- A CONTROLLED TRIAL OF THE TREATMENT OF MYCOBACTERIUM ULCERANS INFECTION WITH CLOFAZIMINEThe Lancet, 1973
- Rifampicin In Experimental Mycobacterium Ulcerans InfectionJournal of Medical Microbiology, 1972